PRN Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis.

Background And Objective: Ranibizumab (Lucentis; Genentech, South San Francisco, CA) is used off-label for the treatment of choroidal neovascularization secondary to ocular histoplasmosis syndrome (OHS). This study prospectively evaluates the safety and efficacy of two treatment paradigms utilizing ranibizumab 0.5 mg: one or three initial injections followed by monthly visits with PRN treatment through Month 12.

A retrospective study evaluating the impact of formal laparoscopic training on patient outcomes in a residency program.

Study Objective: To evaluate the impact of a formal laparoscopic training program on patient outcomes in an obstetrics and gynecology residency.

Design: Retrospective cohort study (Canadian Task Force classification II-1).

Setting: University-affiliated public hospital.

Group A beta-hemolytic Streptococcus as a cause of toxic shock syndrome. A case report.

Group A beta-hemolytic Streptococcus (pyogenes) has been associated recently with toxic-shock-like syndrome similar to staphylococcal toxic shock as described originally in 1978. A group A beta-hemolytic streptococcal infection occurred in a recent postpartum patient and clinically resembled staphylococcal toxic shock.